Incident hyperglycaemia among older adults with or at-risk for HIV infection

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 181-188

  Polsky, Sarit ^a   Floris Moore, Michelle ^b   Schoenbaum, Ellie E ^c   Klein, Robert S ^d   Arnsten, Julia H ^c   Howard, Andrea A ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLUCOSE; PROTEINASE INHIBITOR;

ABDOMINAL OBESITY; ADULT; AGE; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK FACTOR; SCREENING;

ADULT; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PREDIABETIC STATE; RISK FACTORS;

EID: 79953190406     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1711     Document Type: Article

References (44)

1. Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
2. Palacios R, Santos J, Ruiz J, Gonzalez M, Marquez M. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case-control study. AIDS 2003; 17:933-935. (Pubitemid 36547672)
3. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739-1745. (Pubitemid 47237561)
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512. (Pubitemid 47037350)
5. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
6. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119. (Pubitemid 46984626)
7. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33:577-584. (Pubitemid 36975845)
8. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis 2003; 36:1318-1323. (Pubitemid 36629943)
9. de Larrañaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25:98-103. (Pubitemid 43333670)
10. Howard AA, Lo Y, Floris-Moore M, et al. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007; 21:633-641.
11. Yoon C, Gulick RM, Hoover DR, Vaamonde CM, Glesby MJ. Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 37:1464-1469. (Pubitemid 39602336)
12. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005; 40:1492-1499. (Pubitemid 40628638)
13. Howard AA, Floris-Moore M, Lo Y, et al. Abnormal glucose metabolism among older men with or at risk of HIV infection. HIV Med 2006; 7:389-396. (Pubitemid 44123250)
14. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45:66-71. (Pubitemid 46684444)
15. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815-819.
16. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
17. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54:1566-1572.
18. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257-275. (Pubitemid 35278626)
19. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31 Suppl 1:S12-S54.
20. The DECODE-study group, the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42:647-654.
21. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause 2005; 12:348-356. (Pubitemid 40664218)
22. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41:1794-1803. (Pubitemid 41759867)
23. WHO Study Group. Diabetes Mellitus: report of a WHO study group. WHO technical report series 727. Geneva: World Health Organization 1985; pp. 99.
24. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31 Suppl 1:S55-S60.
25. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
26. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139. (Pubitemid 32150958)
27. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services 2009; pp. 120.
28. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227-1234.
29. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18. (Pubitemid 32424384)
30. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144. (Pubitemid 39463678)
31. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649. (Pubitemid 38393463)
32. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
33. Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005; 5:255-262. (Pubitemid 41448371)
34. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:499-505.
35. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898. (Pubitemid 20173164)
36. Rodriguez BL, Lau N, Burchfiel CM, et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999; 22:1262-1265. (Pubitemid 29350234)
37. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22:920-924. (Pubitemid 29241045)
38. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25:1129-1134. (Pubitemid 41071162)
39. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397-405.
40. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
41. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health 2006; 96:1060-1065. (Pubitemid 43825275)
42. Kruzich LA, Marquis GS, Wilson CM, Stephensen CB. HIV-infected US youth are at high risk of obesity and poor diet quality: a challenge for improving short- and long-term health outcomes. J Am Diet Assoc 2004; 104:1554-1560. (Pubitemid 39278116)
43. Karmon SL, Moore RD, Dobs AS, et al. Body shape and composition in HIV-infected women: an urban cohort. HIV Med 2005; 6:245-252. (Pubitemid 41025289)
44. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.